SECURITIES AND EXCHANGE COMMISSION
                             Washington, D.C. 20549



                                    FORM 8-K
                                 CURRENT REPORT



     Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934



         Date of Report (Date of earliest event reported) April 30, 2003



                        Progenics Pharmaceuticals, Inc.
             (Exact name of registrant as specified in its charter)



              Delaware              000-23143                  13-3379479
    (State or other jurisdiction    (Commission             (IRS Employer
         of incorporation)          File Number)         Identification No.)



             777 Old Saw Mill River Road, Tarrytown, New York 10591
               (Address of principal executive offices) (Zip Code)


        Registrant's telephone number, including area code (914) 789-2800


         (Former name or former address, if changed since last report.)







Item 7.  Financial Statements and Exhibits

(c) Exhibits

         Exhibit 99.1      Description
                           Press Release dated April 30, 2003 (filed herewith).


Item 9. Regulation FD Disclosure.

         On April 30, 2003, Progenics Pharmaceuticals, Inc. issued a press
release announcing top-line results from a phase 2 clinical trial of its
investigational drug methylnaltrexone for the treatment of opioid-induced
constipation. A copy of the press release is attached as Exhibit 99.1.

         The information furnished pursuant to Item 9 in this Form 8-K shall not
be deemed to be "filed" for the purposes of Section 18 of the Securities
Exchange Act of 1934 or otherwise subject to the liabilities of that Section,
unless we specifically incorporate it by reference in a document filed under the
Securities Act of 1933 or the Securities Exchange Act of 1934. We undertake no
duty or obligation to publicly update or revise the information furnished
pursuant to Item 9 in this Form 8-K.









                                   SIGNATURES

                  Pursuant to the requirements of the Securities Exchange Act of
1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized.

                               PROGENICS PHARMACEUTICALS, INC.


                               By:  /s/ PHILIP K. YACHMETZ
                                   ------------------------
                                   Philip K. Yachmetz
                                   Vice President, General Counsel and Secretary


Date:  April 30, 2003